Clinical Trial Update: Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial update for HX008, a recombinant human anti-PD-1 monoclonal antibody, in advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• HX008

Snippet

Sponsor: Taizhou Hanzhong biomedical co. LTD | Conditions: Advanced Solid Tumor | Phase 2 | Status: UNKNOWN